Cargando…
Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
BACKGROUND: Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial hemorrhage (ICH) is a concern with IA or intravenous (IV) adminis...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184064/ https://www.ncbi.nlm.nih.gov/pubmed/21933438 http://dx.doi.org/10.1186/2040-7378-3-10 |
_version_ | 1782213050896482304 |
---|---|
author | Crumrine, R Christian Marder, Victor J Taylor, G McLeod LaManna, Joseph C Tsipis, Constantinos P Scuderi, Philip Petteway, Stephen R Arora, Vikram |
author_facet | Crumrine, R Christian Marder, Victor J Taylor, G McLeod LaManna, Joseph C Tsipis, Constantinos P Scuderi, Philip Petteway, Stephen R Arora, Vikram |
author_sort | Crumrine, R Christian |
collection | PubMed |
description | BACKGROUND: Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial hemorrhage (ICH) is a concern with IA or intravenous (IV) administration especially as the therapeutic window is extended. However, because IA administration delivers a higher local concentration of agent, the incidence and severity of ICH may be greater than with similar doses IV. We investigated the safety of rt-PA administration by IA compared to IV infusion following 6 hours of MCA occlusion (MCAo) with reflow in the spontaneously hypertensive rat (SHR). METHODS: Male SHRs were subjected to 6 hours MCAo with 18 hours reflow using a snare ligature model. They were treated with IA saline, IA rt-PA (1, 5, 10, 30 mg/kg), or IV rt-PA (10 and 30 mg/kg) by a 10 to 60 minute infusion beginning approximately 1 minute before reflow. The rats were recovered for 24 hours after MCAo onset at which time Bleeding Score, infarct volume, and Modified Bederson Score were measured. RESULTS: Greater hemorrhagic transformation occurred with 10 and 30 mg/kg rt-PA administered IA than IV. The IV 10 mg/kg rt-PA dosage induced significantly less bleeding than did the 1 or 5 mg/kg IA groups. No significant increase in infarct volume was observed after IA or IV treatment. Rats treated with 30 mg/kg rt-PA by either the IA or IV route had greater neurological dysfunction compared to all other groups. CONCLUSIONS: Administration of rt-PA by the IA route following 6 hours of MCAo results in greater ICH and worse functional recovery than comparable dosages IV. Significantly greater bleeding was observed when the IA dose was a tenth of the IV dose. The increased bleeding did not translate in larger infarct volumes. |
format | Online Article Text |
id | pubmed-3184064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31840642011-10-01 Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model Crumrine, R Christian Marder, Victor J Taylor, G McLeod LaManna, Joseph C Tsipis, Constantinos P Scuderi, Philip Petteway, Stephen R Arora, Vikram Exp Transl Stroke Med Research BACKGROUND: Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial hemorrhage (ICH) is a concern with IA or intravenous (IV) administration especially as the therapeutic window is extended. However, because IA administration delivers a higher local concentration of agent, the incidence and severity of ICH may be greater than with similar doses IV. We investigated the safety of rt-PA administration by IA compared to IV infusion following 6 hours of MCA occlusion (MCAo) with reflow in the spontaneously hypertensive rat (SHR). METHODS: Male SHRs were subjected to 6 hours MCAo with 18 hours reflow using a snare ligature model. They were treated with IA saline, IA rt-PA (1, 5, 10, 30 mg/kg), or IV rt-PA (10 and 30 mg/kg) by a 10 to 60 minute infusion beginning approximately 1 minute before reflow. The rats were recovered for 24 hours after MCAo onset at which time Bleeding Score, infarct volume, and Modified Bederson Score were measured. RESULTS: Greater hemorrhagic transformation occurred with 10 and 30 mg/kg rt-PA administered IA than IV. The IV 10 mg/kg rt-PA dosage induced significantly less bleeding than did the 1 or 5 mg/kg IA groups. No significant increase in infarct volume was observed after IA or IV treatment. Rats treated with 30 mg/kg rt-PA by either the IA or IV route had greater neurological dysfunction compared to all other groups. CONCLUSIONS: Administration of rt-PA by the IA route following 6 hours of MCAo results in greater ICH and worse functional recovery than comparable dosages IV. Significantly greater bleeding was observed when the IA dose was a tenth of the IV dose. The increased bleeding did not translate in larger infarct volumes. BioMed Central 2011-09-20 /pmc/articles/PMC3184064/ /pubmed/21933438 http://dx.doi.org/10.1186/2040-7378-3-10 Text en Copyright ©2011 Crumrine et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Crumrine, R Christian Marder, Victor J Taylor, G McLeod LaManna, Joseph C Tsipis, Constantinos P Scuderi, Philip Petteway, Stephen R Arora, Vikram Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model |
title | Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model |
title_full | Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model |
title_fullStr | Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model |
title_full_unstemmed | Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model |
title_short | Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model |
title_sort | intra-arterial administration of recombinant tissue-type plasminogen activator (rt-pa) causes more intracranial bleeding than does intravenous rt-pa in a transient rat middle cerebral artery occlusion model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184064/ https://www.ncbi.nlm.nih.gov/pubmed/21933438 http://dx.doi.org/10.1186/2040-7378-3-10 |
work_keys_str_mv | AT crumrinerchristian intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel AT mardervictorj intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel AT taylorgmcleod intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel AT lamannajosephc intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel AT tsipisconstantinosp intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel AT scuderiphilip intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel AT pettewaystephenr intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel AT aroravikram intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel |